Nippon India pharma fund (Equity, Equity Sectoral-pharma)

15 yrs 12 monthsStarted on:05 Jun 2004
₹ 2850.69 Cras on: 21 May 2020
Long Term Horizon
Capital Appreciation

Minimum Investment

  • ₹ 5000.00 for Lumpsum

Investment Objective

The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.

Exit Load

No entry load will be charged for Subscriptions/Switch Ins W.E.F August 01, 2009. Exit Load for all subscriptions W.E.F August 24, 2009 is 1% if redeemed/Switched out on or before completion of 1 year from the date of allotment

Scheme Documents

Similar Funds
UTI Healthcare Fund
Current NAV 101.82
Return (CAGR) 13.22%
Value Research NA
SBI Healthcare Opportunities Fund
Current NAV 140.55
Return (CAGR) 14.90%
Value Research NA
TATA India Pharma & Health Care Fund
Current NAV 10.96
Return (CAGR) 2.11%
Value Research NA


TenureReturns (CAGR)
1 Month1.62
3 Month11.13
1 YR29.14
2 YR17.24
3 YR12.77

SIP Returns

TenureReturns (CAGR)
1 YR49.71
2 YR21.8
3 YR16.85
5 YR10.29
10 YR13.29


Company Name% Assets
Aurobindo Pharma Ltd.10.98
Dr. Reddy's Laboratories Ltd.10.36
Sun Pharmaceutical Inds. Ltd.10.27
Divi's Laboratories Ltd.9
Cipla Ltd.7.86
Lupin Ltd.7.33
Syngene International Ltd.4.86
Sanofi India Ltd.4.77
Fortis Healthcare (India) Ltd4.72
Thyrocare Technologies Ltd.4.53

Top Sectoral Holdings

Sector Name% Assets


Portfolio turnover ratio27
Standard Deviation20.67%
Sharpe Ratio0.34

Sailesh Raj Bhan

Mr. Bhan is an MBA (Finance) and CFA.
Mr. Sailesh Raj Bhan has about 19 years experience in equity research and fund management, with over 10 years at Reliance Nippon Life Asset Management Limited (formerly Reliance Capital Asset Management Limited). He manages diversified equity schemes like Reliance Equity Opportunities Fund (the largest Flexicap Scheme in India with assets of USD 800 million) since its inception in 2005 and Reliance Top200 Fund (a large cap diversified equity fund) since its inception in 2007. In addition, for over 9 years, he has been managing two specialized sector funds - Reliance Pharma Sector Fund (the largest pharma sector fund in India) and Reliance Media and Entertainment Fund.

Other Funds Managed by Sailesh Raj Bhan